Pharmaceutical Pricing and Distribution in Japan: The keys to success in the world’s second largest market

No serious multinational can afford to ignore Japan, but it remains a tough and highly competitive market to crack, with the environment for developing and marketing medicines dominated by price. Virtually no new prescription brand can be introduced without a yakka (reimbursement price) set by the government. Innovative new drugs receive price premiums while others are capped at the price of older entrants. Discounting to the trade is inescapable, but is punished by downward price revisions on a scale and frequency unseen elsewhere. Big selling brands and now others in the same class are subject to special price cuts. Distribution is inherently linked to the pricing process and is particularly opaque to outsiders. Whether the challenge is entering the Japanese market for the first time, moving up the all-important ranking there by market share, or negotiating with a local in-licensing partner, this report is designed to help. New drug pricing and price revision processes explained Written by an acknowledged expert on the Japanese market with 20 years’ experience Fully researched through field interviews conducted in Tokyo and Osaka with industry leaders, government officials and others during March 2008 Incorporates all pricing rule changes that came into effect from April 2008 Pro-generic measures critically appraised Key role of wholesalers and how they are paid clarified Prospects for future reform to the P&R processes discussed

http://www.aarkstore.com/reports/Pharmaceutical-Pricing-and-Distribution-in-Japan-The-keys-to-success-in-the-world’s-second-largest-market-1046.html

Access to Hospital Pharmaceutical Markets in the United Kingdom – Aarkstore Enterprise

Public hospitals represent a very important market segment for most biopharmaceutical companies in Europe. They are the often the only market for the increasing numbers of speciality drugs emerging from R&D, with many primary care products also unable to get established for maintenance therapy in the community without hospital recommendation first. Though the processes for achieving hospital usage are very different to the reimbursed GP/community pharmacy sector, they have been poorly documented and often little understood. This justpharmareports’ publication aims to clarify the situation for the UK, a particularly challenging country with four different public healthcare systems, numerous stakeholders, regular reforms, and rigorous health technology assessment.

Medicines prescribed in English hospitals in 2006 were valued at £2.7 billion. This represented 24% of the English NHS drugs bill (hospital prescribing in London alone accounted for 40% of all prescribing costs in the capital). Even more significantly, the hospital drug bill has been rising at more than twice the rate of GP prescribing costs.

‘Access to Hospital Pharmaceutical Markets in the UK’ provides:

• Comprehensive and clear information on how medicines for hospital use get selected, purchased, distributed, prescribed, dispensed and paid for.
• Separate sections on England, Scotland, Wales and Northern Ireland.
• Full coverage of the NHS plus two of the largest private providers.
• Explanation of tendering, contracting, contract adjudication and other aspects of procurement for both brands and generics.
• Clarification of the complex English funding system, Payment by Results.
• Special focus on oncology.

• What discounts hospitals expect and why value-added tax is a concern.
• Features on risk-sharing schemes and on the boom in homecare services.
• NICE, SMC, AWMSG, the PPRS and much, much more

http://www.aarkstore.com/reports/Access-to-Hospital-Pharmaceutical-Markets-in-the-United-Kingdom-1052.html

Pharmacy Liberalisation in Europe: Prospects and Implications – Aarkstore Enterprse

Very little in the pricing environment in Europe is predictable to pharmaceutical companies and only rarely is much notice given of change. But before the end of 2009, if the European Court of Justice accepts the arguments put to it forcefully by the European Commission and by DocMorris, revolutionary reform among industrys main customer group, the community pharmacist, in several of the main countries, including 4 of the EU-5, will get the green light. The main issue to be resolved, whether national regulations on pharmacy ownership and establishment of new premises infringe EU law, is of wider importance than for the pharmacy profession alone. It amounts to a battle over control of healthcare provision between Brussels and the member states, with the outcome also of great significance to patients, wholesalers, manufacturers and payers.

Pharmacy Liberalisation in Europe: Prospects and Implications provides fully-researched, up-to-date information and interpretation on what deregulation could mean to all participants in the medicines market. Whether your interest is in marketing prescription brands, generics or OTCs, in their distribution, or in paying the bill for them, this report is for you. To be forewarned of what might happen will allow adequate preparation for it.

The report addresses:

• Background and current status of infringement actions brought by the European Commission against seven EU member states, plus the key ECJ case involving the controversial DocMorris pharmacy in the German city of Saarbrücken.
• The arguments for and against reform.
• What might happen, who would be the winners and the losers.
• Details of the current ownership structure, and ownership and establishment rules for pharmacies in countries all across Europe from Iceland to Cyprus.
• Interdependency of pharmacy and wholesaling, and how this could evolve.
• What lessons can be found from markets that have already deregulated.
• How vertical integration impacts reimbursement of multisource products and the response by payers to this.
• The latest on plans to break up Apotekets pharmacy monopoly in Sweden.

http://www.aarkstore.com/reports/Pharmacy-Liberalisation-in-Europe-Prospects-and-Implications-1050.html

Wound Care Markets, 4th. Edition, Vol. I: Skin Ulcers – Aarkstore Enterprise

Wound care is a constantly changing market. The trend toward cost-effective skin ulcer treatment remains embedded in management programs that emphasize prevention and early intervention. New wound care products and devices are entering the market with lightening speed, all striving for the best clinical outcomes. Kalorama’s Wound Care Markets, 4th Edition, Vol. I: Skin Ulcers. represents the fourth time that Kalorama has rexamined this aspect of the wound care market, and the study analyzes the market using the following product segments and subsegments:

• Anti-Infectives
  • Systemic
  • Topical
• Skin Ulcer Management
  • Compression Dressings and Bandages
  • Wound Cleaners
  • Debridement
• Moist Dressings
  • Alginates
  • Films
  • Foams
  • Hydrocolloids
  • Hydrogels
• Negative Pressure Wound Therapy
• Biological Dressings
  • Artificial Skin
  • Collagen
  • Growth Factors
  • Others
• Pressure Relief
• Miscellaneous Treatments

For each segment and subsegment, the report gives current market size and forecasted revenues years 2009 through 2013. Competitive market share information is provided by leading manufacturer for each major segment in the year 2006. Historical data are provided for each of the years 2003 through 2008. The study also details research developments, industry trends, and relevant epidemiologic and demographic data.

Since the last edition of Kalorama Information’s Wound Care Markets Series, there have been shifts in the market for treatment of skin ulcers. Up-to-date information was obtained from coverage of the world-renown Symposium on Advanced Wound Care and the Wound Healing Society convention. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals and company reports and releases. Key information from published literature was used to conduct interviews with over 62 industry executives and product managers to validate and obtain expert opinion on current and future trends in the wound care industry. Interviews were also used to confirm and/or adjust market size and market share estimates, as well as in formulating market projections.

All market data pertain to the market at the manufacturers’ level. Data are expressed in current U.S. dollars.

Marketing directors, product managers, business development executives in the wound care industry, investment specialists considering investments in this area and consultants and advertising agencies who service wound care clients are among those who will find this study a useful resource.

License Note: Kalorama Information’s listed default price on its information products reflects a single user license only. Purchasing a departmental or global site license (for entire company) permits multiple individuals in the company to benefit from this resource.

http://www.aarkstore.com/reports/Wound-Care-Markets-4th-Edition-Vol-I-Skin-Ulcers-13480.html

Complete Guide to the 2009 PPRS, NICE & other Pharmaceutical Cost Containment Measures in the United Kingdom

In an otherwise volatile pharmaceutical world, 2009 has seen two notable and durable anniversaries, the implementation of the tenth re-negotiated Pharmaceutical Price Regulation Scheme in January and the tenth birthday of the National Institute for Health and Clinical Excellence in April. PPRS and NICE, are among abbreviations most widely recognised, but their structures, functions and ways of working are often less than fully understood.

‘Complete Guide to the 2009 PPRS, NICE & other Pharmaceutical Cost Containment Measures in the UK’ delivers what it says in the title. It provides in one place fully-researched, up-to-date information and interpretation on all the market access barriers facing pharmaceutical companies in the four countries that make up the United Kingdom.

The UK has a much bigger global impact in pricing and health technology assessment terms than its market size would suggest. It is a key lead-off one for launches. While accounting for less than 4% of world demand for prescription medicines, other countries that set prices with reference to those in the UK together account for 25% of that demand. Like them or hate them, the PPRS and NICE are original, well-established and influential models that governments and industry bodies elsewhere look to.

The report addresses:

• The UK’s complex decision-making processes for funding of medicines.

• The procedures and outcomes of the three HTA bodies, NICE, SMC and AWMSG.

• How and why the 2009 PPRS evolved in the way it did, and what this means for companies selling medicines to the NHS.

• The pros and cons of joining the voluntary or alternative statutory scheme.

• All the changes in the new PPRS and the prospects for the more novel but contentious parts, including flexible pricing, patient access schemes and generic substitution.

• What jargon including ‘end-of-life treatment’, ‘horizon scanning’, ‘NICE blight’,‘OFT wedge’ ‘outturn’, ‘QALY’, ‘safety value’ and ‘top-up’ actually mean.

• Other cost containment measures impacting on prescribers, patients and the distribution chain.

http://www.aarkstore.com/reports/Complete-Guide-to-the-2009-PPRS-NICE-other-Pharmaceutical-Cost-Containment-Measures-in-the-United-Kingdom-13490.html

UK Consumer Insights 2009: Homebase – DIY – Aarkstore Enterprise

UK Consumer Insights 2009 are based around individual retailers and provide a highly detailed, data-rich overview of a retailer’s customers, drawing on a nationwide survey of 6,000 shoppers each year.

Reasons to Purchase

*New analysis, unique to these reports shows details about non-converting visitors including where they main shop and who they are.
*Analysis by non-standard demographics is also presented to give a comprehensive picture of a retailer’s customers.
*Key demographics include among others, sex, age, social class, television region, marital status, housing tenure, working status and ACORN group.
 
 
Table of Contents : 
“About the cDNA programme 3

Section 1: At a glance summary 4
- At a glance summary 5

Section 2: Share of shoppers 6
- Homebase share of shoppers 7
- Homebase share of shoppers by demographics 8
- Homebase share of shoppers by television region 9
- Homebase share of shoppers by household characteristics 10
- Homebase share of shoppers by other characteristics and ACORN classification 11

Section 3: Conversion and non-conversion 12
- Homebase conversion of visitors to main users 13
- Homebase conversion of visitors to main users by demographics and region 14
- Homebase conversion of visitors to main users by household characteristics 15
- Non-converting customers 16
- Profile of Homebase non-converting customers by demographics and region 17

Section 4: Shopper profiles 18
- Homebase profile of shoppers by demographics 19
- Homebase profile of shoppers by television region 20
- Homebase profile of shoppers by household characteristics 21
- Homebase profile of shoppers by other characteristics and ACORN classification 22

Section 5: Loyalty 23
- Homebase loyalty of main users 24
- Homebase loyalty of main users by demographics and region 25
- Homebase loyalty of main users by household characteristics 26
- Homebase basic drivers of loyalty and disloyalty 27
- Homebase detailed drivers of loyalty 28

Section 6: Competition 29
- Competition in DIY 30
- Cross sector competitor dynamics 31

Appendix 32
Basic Methodology 33
Detailed Methodology 34″

For More Information Kindly Visit Below Link :
http://www.aarkstore.com/reports/UK-Consumer-Insights-2009-Homebase-DIY-15650.html

Top 10 Medical Device Technology – Aarkstore Enterprise

Technological innovations in the medical device industry have led to a radical transformation in patient care. This report identifies the sectors with the industry’s most important developments related to patient care, clinical outcomes, and new product development. While the scope of the report is limited to the top ten technologies only, it covers almost the entire medical device market.

Scientific and medical technology breakthroughs – such as minimally invasive surgery (MIS) – have accelerated the accuracy of clinical outcomes and have also reduced recovery times and the medical costs borne by patients. This has led to radical transformation in patient care.

IT integration in medical imaging and medical devices has given a significant boost to the healthcare industry, a trend that is apparent in the market growth of drug eluting stents and telemedicine technologies. The markets covered in the report have a current potential of $454.3 billion and are expected to grow at a CAGR of 9.8% between 2009 and 2014.

Market estimates and forecast
The report provides in-depth market estimates and forecast for top ten medical device technologies as follows:
• Diagnostic imaging (nuclear imaging, interventional radiology, capsule endoscopy and others)
• Drug delivery (needle free injections, transdermal systems, inhalation system, infusion system)
• Molecular diagnostics (biosensors, proteomics, nanotechnology, and others)
• Mobility aid technologies
• Minimal/non-invasive surgery (stents, bariatric surgery, medical robotics and others)
• Micro-fluids and MEMS (Miniature medical pressure sensors, bio chips, protein chips)
• Non-invasive monitoring (continuous blood glucose monitoring)
• Biomaterials (bionic limbs, joint replacement, antimicrobial wound dressing and others)
• Bio-implants (neurostimulation and others)
• Tele-medicines

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 100 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 50 company profiles for each of its sub-segments.
What makes our reports unique?
• We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
• Each report is about 250 pages with 100+ market data tables, 40 competitive company profiles, analysis of 300 patents and minimum 50 micro markets, which are collectively exhaustive and mutually exclusive.
• No single report by any other publisher provides market data for all the segments viz products, services, applications, ingredients, technology, and stakeholders in a single report for all the four geographies – US, Europe, APAC, ROW.
• We provide 10% customization – Research shows that more than 40% of the times, clients do not get the specific intelligence they need in multi-client market research reports. We offer 10% customization in our reports at no extra cost. Get the exact market intelligence you require with real value for money.
• 15 pages of high level analysis including benchmarking strategies, best practices and the market’s cash cows (BCG matrix). We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
• Comprehensive market analysis for pharmaceutical and biotech companies, medical device manufacturers, pharma-research labs, doctors, physicians and hospitals, medical/pharma associations, retailers and super-retailers, technology providers, and research and development (R&D) companies.

Key questions answered
• Which are the high-growth segments/cash cows and how is the market segmented in terms of applications, products, services, ingredients, technologies, and stakeholders?
• What are market estimates and forecasts; which markets are doing well and which are not?
• Where are the gaps and opportunities; what is driving the market?
• Which are the key playing fields? Which are the winning edge imperatives?
• How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?

Powerful Research and Analysis
The analysts working come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.

For More Information, Kindly Visit :
http://www.aarkstore.com/reports/Top-10-Medical-Device-Technology-27527.html

The Canadian Pharmaceutical Market Outlook to 2013: Policy environment, market structure, pipeline analysis, growth opportunities – Aarkstore Enterprise

The Canadian Pharmaceutical Market Outlook to 2013: Policy environment, market structure, pipeline analysis, growth opportunities

This report provides comprehensive coverage of the Canadian market, incorporating an overview of the country, its socioeconomic status and the epidemiological scenario of major pathophysiological disorders. Furthermore, the report analyzes the scenario in Canada pertaining to pharmaceutical regulation, pricing and reimbursement. Finally, the report analyzes the marketed product portfolios, R&D pipelines and market share data of the leading pharmaceutical companies in Canada, and provides sales forecasts.

Table of Contents :

Pharmaceutical distribution
Independent pharmacy distributors (IPD)
Self-distributors
Retail and hospital pharmacies
Independent pharmacies
Pharmacy groups
Hospital pharmacies
Pharmaceutical sales and market analysis
Drug sales by province and territory
Licensing trends
Market analysis by therapeutic area
Market analysis by drug classes
Market analysis by leading brands
Market analysis by key players
Branded drug manufacturers
Pfizer Canada
Sales analysis by therapeutic area
Sales analysis of leading brands
J&J Canada

For more information, kindly visit :
http://www.aarkstore.com/reports/The-Canadian-Pharmaceutical-Market-Outlook-to-2013-Policy-environment-market-structure-pipeline-analysis-growth-opportunities-13976.html

The Scandinavian Pharmaceutical Market Outlook to 2013: Policy environment, market structure, pipeline analysis, growth opportunities – Aarkstore Enterprise

The Scandinavian Pharma Market Outlook to 2013: Policy environment, market structure, pipeline analysis and growth opportunities

The Scandinavian healthcare system and pharmaceutical market is well regulated, with the state bearing responsibility for a large proportion of an individual’s pharmaceutical expenses. Solidarity and equality are the ideological basis of these welfare states, and a significant public commitment exists towards ensuring access to high quality health care for all citizens. Sweden and Denmark have been the two biggest pharma and biotech markets in Scandinavia, while regional players such as Novo Nordisk have laid the foundations for this industry in the region.

‘The Scandinavian Pharmaceutical Market Outlook to 2013’ is a report published explores the healthcare systems and policy environments of Denmark, Norway, Sweden and Finland. This report examines the region’s market potential by assessing historic epidemiological data, sales trends, competitive intelligence and clinical data across each major country. The growth drivers of the region are identified and forecasts for major prescription drugs and markets are provided for the period 2009-13. The competitive landscape of the Scandinavian market is also evaluated, with the region’s five leading companies being assessed based upon their marketed product portfolios and R&D pipelines in order to forecast their future competitive positions.

Key Findings

The Scandinavian pharma market recorded sales of $10.1bn in 2007, a 16% increase over 2006. Sweden had the largest market share (38%), followed by Finland (23%), Denmark (22%), and Norway (17%). These countries possess developed infrastructures, advanced technologies, R&D support and business friendly cultures. Pfizer led the Scandinavian market in 2007 with sales of $696m, a 6.3% increase over 2006.

Pfizer has a significant presence in all four Scandinavian markets and in the leading therapeutic areas of the region. Drugs for the treatment of CNS disorders are the largest product class in Scandinavia, with a market share of 20.7% in 2007. Cancer and cardiovascular diseases are the next largest therapeutic categories in the region.

Well-developed biotech and life sciences clusters across the Scandinavian region enable world-class research and provide pools of well-educated personnel and versatile facilities to support start-up companies.

Parallel trade has become a major concern for the profitability of Scandinavia-based Pharma companies in recent years. Factors driving this include lower prescription drug expenditures sought by payors and parallel traders’ strategies benefit from price differentials for drugs across different countries.

Use this report to…

• Compare the healthcare markets of key Scandinavian countries with this report’s macroeconomic analysis of infrastructure, per capita health expenditure and Pharma sales growth vs. GDP growth across Sweden, Finland, Denmark and Norway.

• Understand how healthcare policy environments vary across the region with this report’s examination of drug approval processes, pricing regulations and reimbursement policies in each major country.

• Identify which indications have the greatest potential to provide franchise growth with this report’s evaluation of major therapy/sub-therapy areas and leading brands, including forecast sales over the period 2009-2013.

• Measure the performances and prospects of leading companies in the Scandanavian area with this report’s strategic analysis of leading pharma corporations based on sales focus by drug class, currently marketed products and R&D pipeline portfolios.

Explore issues including…

The threat to EU health spending. Pharma activity in the Scandinavian market is focused around cost containment, but in recent years the consumption of generics and parallel imports has slowly increased. A new pricing regime linked to other European countries has also had a moderating effect on price levels in Scandinavian countries over recent years.

Higher licensing deal values. Competition for promising projects (particularly drugs that have established solid proof-of-concept data) has not only boosted the deal values overall, but also increased the quantity and average value of deals in the early stages of product development.

Parallel trade influencing pricing. The prevalence of parallel trade is having a significant impact upon state expenditure on drugs and consumer prices. In Sweden, parallel imports have been included as substitutable products in accordance with the generic substitution policy, giving significant boost to parallel imported products in the country.

Support for generic substitution of patented drugs. A report by the National Trade Estimate of the United States Trade Representative (USTR) made special mention of Finland, due to the country’s Pharma Pricing Board not always waiting for the expiry of the analogous process patent before taking action.Discover…

• What will be the major growth drivers in the Scandinavian pharma market over 2009-13?

• Which companies were the winners and losers in the Scandinavian pharma market in 2007?

• Which companies will become key players over 2009 -13?

• Which products will be affected by generic competitors over the period 2009-13?

• Which pipeline products will be the growth drivers of the future?

• Which therapy areas and indications have the highest market potential over 2009-13?

• How will the Scandinavian pharma market’s competitive landscape change by 2013?

 For more information, kindly visit :
http://www.aarkstore.com/reports/The-Scandinavian-Pharmaceutical-Market-Outlook-to-2013-Policy-environment-market-structure-pipeline-analysis-growth-opportunities-13979.html

Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROI – Aarkstore Enterprise

Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROIs

Offshoring and outsourcing have become an increasingly critical contributor to pharma and biotech R&D strategies in recent years. They enable companies to focus on core competencies such as drug discovery or technology development whilst contracting out non-core processes to experts, often at lower costs. As offshore investments begin to mature and provide returns on investment, the opportunity to migrate individual components or whole segments of R&D portfolios will continue to rise.

‘Key Trends in Offshoring Pharmaceutical R&D’ is a report published evaluates the offshore R&D strategies that can reduce development times and improve productivity, with analysis of a variety of strategic partnerships, academic collaborations, and outsourcing opportunities. This report identifies emerging areas of technological and scientific significance across the globe and examines the offshore strategies and investments of the top 20 pharma and biotech companies across Asia, Australia, Central and Eastern Europe, Latin America and the Far East. This report also provides a financial and managerial valuation of leading companies based on their P/E ratio, return on assets (ROA) and return on investment (ROI) and measures company performance against the healthcare industry, pharmaceutical and biotechnology sectors and leading shares of the S&P500.

Key Findings

• Companies that have allocated over 60% of their R&D expenditure offshore have displayed greater shareholder return, operating margins, market capital growth and return on assets.

• The US currently attracts 53% of total industry R&D spend, however it is forecast that 20% of this expenditure will migrate to Asia Pacific by 2010. Australia, China and Singapore are emerging as key areas for scientific and technological investment.

• Leading pharma and biotech companies have undergone major R&D restructuring over the last five years and now adopt a focused, streamlined global approach which is increasingly reliant on offshore strategic partnerships, academic collaboration and outsourcing to establish networks of scientific expertise.

• Scientific and technological excellence within emerging economies is a key incentive for offshore investment, enabling companies to enhance innovation and productivity within their R&D programs.

• Managerial expertise is a critical factor driving the success of offshore investments, helping leading pharma and healthcare companies to outperform their peers and the S&P 500 index in 2008.

Use this report to…

• Assess the offshore R&D strategies of the top 20 pharma and biotech companies with this report’s analysis of offshore investment and deal trends over the last five years.

• Discover which geographic regions have the greatest potential for offshore R&D investment by identifying key areas of technological, scientific and academic expertise across Asia Pacific, Australia, Eastern Europe, Latin America, the Middle East and South Africa.

• Measure how the offshore strategies of the top 20 pharma and biotech companies have influenced their R&D productivity and efficiency with this report’s financial and managerial performance review, comparative analysis of healthcare/pharma/biotech sectors and S&P500 index assessment.

• Identify the key drivers and opportunities for offshore investment with this report’s analysis of major offshoring trends and R&D developments.

Explore issues including…

Shifting focus of R&D strategies. The industry has become more globalized in its R&D approach as part of efforts to improve productivity and efficiency. Networks of offshore partnerships and academic collaborations are now enabling companies to harness external expertise on a project by project basis.

Offshore investment in emerging economies. Companies are increasingly turning to emerging countries to counter the slowing growth of US and European markets. Investing in offshore R&D facilities provides companies with local expertise and a greater understanding of local economies.

Offshore opportunities in tertiary economies. The success of commercial opportunities in emerging markets has expanded the regional scope of investment, with Australia, Israel and Singapore all seen to provide labour arbitrage and access to specialists.

Focused managerial directives are critical. Successful R&D performance is underpinned by a streamlined R&D strategy which is well managed by a team of scientists, technologists and non-scientists which can guide global networks ensuring early go/no go decision making which builds on the core competencies of both internal and external researchers.

Discover…

• Which countries are attracting offshore investment?

• Which areas of research and technology are attracting offshore investment?

• How are the leading pharma and biotech companies changing their R&D programs?

• Which major companies and academic institutions have attracted offshore investment?

• What factors are driving offshore investment?

• What is the financial performance of the leading pharma and biotech companies based on P/E ratio compared to their peers and the S&P500?

• Which companies have delivered the best return on assets and return on investment during the last five years?

• How will offshore investment influence R&D productivity in the future?

 For more information, kindly visit :
http://www.aarkstore.com/reports/Key-Trends-in-Offshoring-Pharmaceutical-R-D-Company-strategies-emerging-markets-and-impact-on-ROI-13950.html